Figure 5.

Immunomodulation of EAMG manifestations by oral administration of the dual analog. Stimulation of mice was performed with paired needle electrodes inserted percutaneously at the sciatic notch. CMAPs were recorded during 3 Hz repetitive stimulation (eight stimuli) administrated at supramaximal stimulus intensity. Decrement was calculated as the difference between the first and the fifth CMAP (peak to peak) and was expressed as percent of the first CMAP. Recordings were obtained from at least four locations within the muscle and were considered as positive for myasthenogenic decrement, only if a decremental response of 10% or more was found in at least two different recording sites within the muscle. The Fisher’s exact test was performed to test the null hypothesis of no association between treatment with Lys-262–Ala-207 and response. The probability value was 0.022, which allowed us to reject the null hypothesis.